Skip to content

Maridebart Cafraglutide

DRUG20 trials

Sponsors

Amgen

Conditions

Atherosclerotic Cardiovascular DiseaseDiabetes Mellitus, Type 2Heart Failure With Mildly Reduced Ejection FractionHeart Failure With Preserved Ejection FractionObesityObesity DiseaseObesity or OverweightObstructive Sleep Apnea

Phase 1

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
CompletedNCT04478708
AmgenObesity
Start: 2020-08-07End: 2022-11-18Updated: 2025-12-10
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
CompletedNCT06352892
AmgenObesity
Start: 2024-04-25End: 2024-08-27Updated: 2026-01-08
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
Active, not recruitingNCT07160257
AmgenType 2 Diabetes Mellitus
Start: 2025-08-05End: 2027-03-04Updated: 2026-06-12
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
CompletedNCT07226778
AmgenObesity, Overweight
Start: 2025-10-10End: 2026-05-28Updated: 2026-06-17
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
Active, not recruitingNCT07229157
AmgenObesity, Overweight
Start: 2025-10-22End: 2026-08-26Updated: 2026-01-23
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
CompletedNCT07313761
AmgenOverweight and Obesity
Start: 2025-12-15End: 2026-06-26Updated: 2026-07-16
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
RecruitingNCT07523711
AmgenObesity, Overweight
Start: 2026-04-09End: 2026-11-18Target: 45Updated: 2026-07-01

Phase 2

Phase 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Active, not recruitingNCT06858839
AmgenObesity
Start: 2025-03-12End: 2027-04-16Updated: 2025-10-17
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Active, not recruitingNCT06858878
AmgenType 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Start: 2025-03-17End: 2027-04-16Updated: 2025-12-31
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
Active, not recruitingNCT06987695
AmgenObesity Disease
Start: 2025-06-13End: 2027-07-21Updated: 2025-12-17
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RecruitingNCT07037433
AmgenAtherosclerotic Cardiovascular Disease, Obesity, Overweight
Start: 2025-07-25End: 2030-09-29Target: 12800Updated: 2026-07-10
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
RecruitingNCT07037459
AmgenHeart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Obesity
Start: 2025-06-25End: 2030-09-29Target: 5056Updated: 2026-07-02
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
RecruitingNCT07226765
AmgenObstructive Sleep Apnea
Start: 2025-11-25End: 2028-09-13Target: 250Updated: 2026-06-12
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
RecruitingNCT07225686
AmgenObesity, Obstructive Sleep Apnea
Start: 2025-12-19End: 2028-09-13Target: 250Updated: 2026-06-12
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
RecruitingNCT07575399
AmgenObesity or Overweight
Start: 2026-05-11End: 2028-02-28Target: 300Updated: 2026-07-02
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Not yet recruitingNCT07684235
AmgenObesity, Overweight
Start: 2026-07-29End: 2028-03-19Target: 3200Updated: 2026-07-06
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Not yet recruitingNCT07684144
AmgenDiabetes Mellitus, Type 2, Obesity, Overweight
Start: 2026-07-29End: 2028-03-19Target: 950Updated: 2026-07-06

Related Papers